NEW YORK, Oct. 9 – Myriad Genetics of Salt Lake City said Tuesday it had discovered a drug target for treating cancer using its proteomics technology.
In a statement, Myriad said that the ProNet technology allowed the company to look at protein interactions involved in apoptosis and to apply the knowledge garnered to identifying a target for cancer.
“Pre-clinical studies have demonstrated strong anti-cancer activity without harming normal human cell survival,” the company said in a statement.
Last month the company said that using ProNet it had found a drug target for hepatitis C. Myriad has also used the technique in its efforts to find drug targets for HIV and hepatitis B.
ProNet uses yeast two-hybrid to identify protein-protein interactions and to find intracellular, secreted, and membrane proteins. Myriad said that its system has a false positive rate of less than one percent and higher throughput than other methods.
Myriad, which is currently conducting tests on a prostate cancer drug and a colon cancer, said that it would now deploy its medicinal and organic chemistry capabilities to further develop anti-cancer compounds.